{"id":2538,"date":"2026-08-20T10:33:13","date_gmt":"2026-08-20T02:33:13","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&p=2538"},"modified":"2026-08-20T10:52:39","modified_gmt":"2026-08-20T02:52:39","slug":"hanchorbio-expands-next-generation-immunotherapy-strategy-by-integrating-immune-education-and-macrophage-activation-2","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-expands-next-generation-immunotherapy-strategy-by-integrating-immune-education-and-macrophage-activation-2\/","title":{"rendered":"HanchorBio Expands Next-Generation Immunotherapy Strategy by Integrating Immune Education and Macrophage Activation"},"content":{"rendered":"

HanchorBio Expands Next-Generation Immunotherapy Strategy by Integrating Immune Education and Macrophage Activation<\/strong><\/h2>\n

Exploring vaccine-based immune activation collaborations to combine tumor-specific immune recognition with innate immune activation for cancer and immune-mediated diseases<\/em><\/h3>\n

\u00a0<\/strong><\/p>\n

TAIPEI, SHANGHAI, and SAN FRANCISCO \u2014\u00a0August 20, 2026<\/strong>\u00a0\u2014 HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced the expansion of its immunotherapy strategy to explore vaccine-based immune activation approaches through strategic collaborations in cancer and immune-mediated diseases.<\/p>\n

 <\/p>\n

Recent clinical advances in therapeutic cancer vaccines have highlighted a new era of immunotherapy \u2014 one in which the immune system can be precisely educated to recognize disease-specific targets and generate tumor-directed immune responses. These breakthroughs demonstrate the potential of antigen-specific immune activation to complement existing immunotherapy approaches and further transform cancer treatment.<\/p>\n

 <\/p>\n

However, generating tumor-specific immune responses represents only one critical step in achieving durable anti-tumor immunity. Many solid tumors develop complex immune resistance mechanisms within the tumor microenvironment, including suppression of innate immune function that can limit immune activation, antigen processing, and effective tumor clearance.<\/p>\n

 <\/p>\n

HanchorBio believes the next generation of immunotherapy will require coordinated activation of multiple immune mechanisms\u2014integrating immune education, immune activation, and immune execution<\/strong>.<\/p>\n

 <\/p>\n

HanchorBio\u2019s proprietary FBDB\u2122 (Fc-Based Designer Biologics) platform and lead oncology program, HCB101, are designed to address a complementary immune barrier through macrophage-directed immunotherapy. HCB101 is an engineered SIRP\u03b1-IgG4 Fc fusion protein designed to block the CD47-SIRP\u03b1 innate immune checkpoint and enhance macrophage-mediated anti-tumor activity.<\/p>\n

\"\"<\/p>\n

By activating macrophage function, HCB101 has the potential to complement vaccine-based immune activation approaches by enhancing tumor cell clearance, increasing tumor antigen uptake and processing, promoting immune cell communication, and enhancing the formation of de novo clones of tumor-attacking T cells, including effector memory T cells. HCB101 treatments also reshape the tumor microenvironment to support broader and more durable anti-tumor immune responses.<\/p>\n

 <\/p>\n

\u201cWe are entering a new era of immunotherapy \u2014 one where the future of cancer treatment will be defined not by a single immune pathway, but by coordinated activation of the entire immune system,\u201d said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio<\/strong>. \u201cTherapeutic vaccines offer a powerful approach to educate the adaptive immune system to recognize and attack tumors, while macrophage-directed therapies such as HCB101 have the potential to activate innate immunity, promote the de novo generation of tumor-reactive T-cell clones, and reshape the tumor microenvironment. By bringing these complementary immune mechanisms together, we believe we can create new opportunities to generate more durable and effective immune responses and ultimately make a meaningful difference for patients with cancer and immune-mediated diseases.\u201d<\/p>\n

 <\/p>\n

The emerging next-generation immunotherapy paradigm may involve coordinated activation of three complementary immune functions:<\/p>\n

Immune education<\/strong><\/p>\n

Vaccine-based approaches can generate tumor-specific immune recognition by presenting disease-associated targets to the adaptive immune system.<\/p>\n

Immune reinvigoration<\/strong><\/p>\n

Checkpoint blockade such as anti-PD-1 antibodies can revive T-cell activity and reduce immune exhaustion.<\/p>\n

De Novo Immune processing and remodeling<\/strong><\/p>\n

Macrophage-directed therapies can activate innate immune clearance, enhance antigen processing, promote de novo T-cell activation, and reshape the tumor microenvironment.<\/p>\n

 <\/p>\n

HanchorBio is actively exploring collaborations with innovative partners to evaluate vaccine-based immune activation strategies in combination with its proprietary macrophage-directed platform, with the goal of advancing differentiated therapeutic approaches for oncology and immune-mediated diseases. Potential cancer vaccine partners have been identified, and scientific discussions with those potential partners have been initiated.<\/p>\n

 <\/p>\n

As the field moves beyond PD-1-centered immunotherapy, HanchorBio is exploring strategic collaborations that integrate antigen-specific immune activation with its proprietary macrophage-enhancer technology platform. Through these efforts, HanchorBio aims to advance next-generation immunotherapies designed to overcome multiple mechanisms of immune resistance across oncology and immune-mediated diseases.<\/p>\n

\u00a0<\/strong><\/p>\n

About HCB101<\/strong><\/p>\n

HCB101 is an investigational engineered SIRP\u03b1\u2013IgG4 Fc fusion protein developed using HanchorBio\u2019s proprietary FBDB\u2122 platform. HCB101 blocks CD47\u2013SIRP\u03b1 signaling and is designed to enhance macrophage-mediated antitumor immunity. It is being evaluated as monotherapy (NCT05892718) and in combinations (NCT06771622) across solid and hematologic malignancies. HCB101 has received U.S. FDA Orphan Drug Designation for gastric cancer.<\/p>\n

\u00a0<\/strong><\/p>\n

About HanchorBio<\/strong><\/p>\n

HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases. Its proprietary\u00a0Fc-Based Designer Biologics (FBDB\u2122) platform\u00a0enables the engineering of multifunctional biologics designed to coordinately modulate complementary immune pathways.<\/p>\n

 <\/p>\n

HanchorBio\u2019s pipeline includes clinical-stage programs HCB101 (a SIRP\u03b1-based innate immune checkpoint program) and HCB301 (a trispecific immunotherapy targeting SIRP\u03b1, PD-L1, and TGF-\u03b2 biology), as well as next-generation programs including HCB303 and additional candidates across oncology and immune-mediated diseases. With operations in Taiwan, China, and the United States, HanchorBio integrates therapeutic engineering, translational science, clinical development, and global regulatory execution.<\/p>\n

\u00a0<\/strong><\/p>\n

Forward-Looking Statements<\/strong><\/p>\n

This press release contains forward-looking statements regarding HanchorBio\u2019s clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory decisions, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.<\/p>\n","protected":false},"excerpt":{"rendered":"

HanchorBio announced the expansion of its immunotherapy strategy to explore vaccine-based immune activation approaches through strategic collaborations in cancer and immune-mediated diseases.<\/p>\n","protected":false},"featured_media":2537,"template":"","news-category":[46],"class_list":["post-2538","news","type-news","status-publish","has-post-thumbnail","hentry","news-category-development-progress-2"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/2538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media\/2537"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=2538"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=2538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}